Neos Therapeutics Company Profile (NASDAQ:NEOS)

About Neos Therapeutics

Neos Therapeutics logoNeos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NEOS
  • CUSIP:
Key Metrics:
  • Previous Close: $5.95
  • 50 Day Moving Average: $5.74
  • 200 Day Moving Average: $6.65
  • 52-Week Range: $4.85 - $11.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.84
  • P/E Growth: -0.01
  • Market Cap: $95.56M
  • Outstanding Shares: 16,060,000
  • Beta: -0.92
Profitability:
  • Net Margins: -1,013.17%
  • Return on Equity: -144.74%
  • Return on Assets: -64.00%
Debt:
  • Debt-to-Equity Ratio: 3.68%
  • Current Ratio: 3.36%
  • Quick Ratio: 3.10%
Additional Links:
Companies Related to Neos Therapeutics:

Analyst Ratings

Consensus Ratings for Neos Therapeutics (NASDAQ:NEOS) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.33 (325.77% upside)

Analysts' Ratings History for Neos Therapeutics (NASDAQ:NEOS)
Show:
DateFirmActionRatingPrice TargetDetails
11/11/2016BMO Capital MarketsReiterated RatingBuyView Rating Details
5/18/2016Wells Fargo & CompanyReiterated RatingBuyView Rating Details
5/17/2016Royal Bank of CanadaLower Price TargetOutperform$33.00 -> $29.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$33.00 -> $32.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Neos Therapeutics (NASDAQ:NEOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2017        
8/11/2016Q2($1.16)($1.65)$1.48 million$1.49 millionViewListenView Earnings Details
5/16/2016Q1($0.87)($0.79)ViewListenView Earnings Details
3/17/2016Q4($0.66)($0.57)$1.70 millionViewListenView Earnings Details
9/3/2015Q215($4.31)($7.76)$1.70 million$1.48 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Neos Therapeutics (NASDAQ:NEOS)
Current Year EPS Consensus Estimate: $-5.39 EPS
Next Year EPS Consensus Estimate: $-3.24 EPS

Dividends

Dividend History for Neos Therapeutics (NASDAQ:NEOS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Neos Therapeutics (NASDAQ:NEOS)
Insider Ownership Percentage: 4.85%
Institutional Ownership Percentage: 34.32%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2016Bryant FongDirectorBuy1,500$6.54$9,810.00View SEC Filing  
8/25/2016Richard I EisenstadtCFOBuy3,710$6.82$25,302.20View SEC Filing  
6/13/2016Juergen MartensInsiderBuy10,000$9.90$99,000.00View SEC Filing  
5/19/2016Alan L HellerDirectorBuy10,000$7.61$76,100.00View SEC Filing  
5/19/2016Thomas P McdonnellInsiderBuy3,000$7.56$22,680.00View SEC Filing  
5/18/2016Gregory J RobitailleDirectorBuy7,442$7.55$56,187.10View SEC Filing  
4/20/2016Presidio Partners 2007, L.P.Major ShareholderSell20,367$9.98$203,262.66View SEC Filing  
4/15/2016Presidio Partners 2007, L.P.Major ShareholderSell57,968$10.23$593,012.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Neos Therapeutics (NASDAQ:NEOS)
DateHeadline
biz.yahoo.com logoNEOS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State (NASDAQ:NEOS)
biz.yahoo.com - February 8 at 7:41 PM
News IconFinancial Stock Changes in Focus: Banco Bradesco SA's (BBD) (NASDAQ:NEOS)
xboxonezone.com - February 6 at 11:52 PM
rttnews.com logoNeos Therapeutics Prices Public Offering At $5/Shr (NASDAQ:NEOS)
www.rttnews.com - February 6 at 6:51 PM
streetinsider.com logoPre-Open Movers 02/03: (PXLW) (DATA) (PTN) Higher; (DECK) (IDXG) (FEYE) (GPRO) (AMZN) Lower (more...) (NASDAQ:NEOS)
www.streetinsider.com - February 3 at 7:33 PM
reuters.com logoBRIEF-Neos Therapeutics estimates that, for three months ended Dec. 31 total net product revenues were between $3.3 mln-$3.6 mln (NASDAQ:NEOS)
www.reuters.com - February 3 at 7:33 PM
nasdaq.com logoNeos Therapeutics Announces Pricing of Underwritten Public Offering of $25.0 Million of Common Stock (NASDAQ:NEOS)
www.nasdaq.com - February 3 at 7:33 PM
finance.yahoo.com logoWhy Neos Therapeutics Shares Are Hitting a New Low (NASDAQ:NEOS)
finance.yahoo.com - February 3 at 7:33 PM
4-traders.com logoNEOS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:NEOS)
www.4-traders.com - February 2 at 7:41 PM
finance.yahoo.com logoNeos Therapeutics Announces Proposed Offering of Common Stock (NASDAQ:NEOS)
finance.yahoo.com - February 2 at 7:41 PM
capitalcube.com logoETFs with exposure to Neos Therapeutics, Inc. : January 20, 2017 (NASDAQ:NEOS)
www.capitalcube.com - January 20 at 7:34 PM
4-traders.com logoNeos Therapeutics : Patent Issued for Compositions and Methods of Making Sustained Release Liquid Formulations (USPTO 9522120) (NASDAQ:NEOS)
www.4-traders.com - December 29 at 6:47 PM
4-traders.com logoNeos Therapeutics : Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHD (NASDAQ:NEOS)
www.4-traders.com - December 21 at 7:36 PM
streetinsider.com logoNeos Therapeutics (NEOS) Completes XR-ODT NDA Resubmission (NASDAQ:NEOS)
www.streetinsider.com - December 20 at 12:44 PM
us.rd.yahoo.com logo7:32 am Neos Therapeutics completes resubmission of a NDA to the FDA for Cotempla XR-ODT (NASDAQ:NEOS)
us.rd.yahoo.com - December 20 at 12:44 PM
publicnow.com logoNeos Therapeutics Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHD (NASDAQ:NEOS)
www.publicnow.com - December 20 at 12:44 PM
biz.yahoo.com logoNEOS THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:NEOS)
biz.yahoo.com - December 20 at 12:44 PM
finance.yahoo.com logoNeos Therapeutics resubmits ADHD drug marketing application (NASDAQ:NEOS)
finance.yahoo.com - December 20 at 12:44 PM
globenewswire.com logoNeos Therapeutics to Present at BMO Prescription for Success Healthcare Conference - GlobeNewswire (press release) (NASDAQ:NEOS)
globenewswire.com - December 7 at 11:45 PM
finance.yahoo.com logoNeos Therapeutics to Present at BMO Prescription for Success Healthcare Conference (NASDAQ:NEOS)
finance.yahoo.com - December 7 at 9:42 AM
News IconWatching Technical Levels on Shares of Neos Therapeutics Inc (NEOS) - Yankee Analysts (NASDAQ:NEOS)
yankeeanalysts.com - December 6 at 11:33 PM
News IconMarket Focus: Checking Indicators on Shares of Neos Therapeutics Inc (NEOS) - Yankee Analysts (NASDAQ:NEOS)
yankeeanalysts.com - December 2 at 6:28 PM
News IconShares in View: Neos Therapeutics Inc (NEOS) - Yankee Analysts (NASDAQ:NEOS)
yankeeanalysts.com - November 30 at 6:56 PM
News IconNeos Therapeutics, Inc. NEOS Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:NEOS)
www.bioportfolio.com - November 24 at 9:39 AM
News IconStock Momentum in Focus on Shares of Neos Therapeutics Inc (NEOS) - Yankee Analysts (NASDAQ:NEOS)
yankeeanalysts.com - November 23 at 6:28 PM
News IconVC Score In Focus for Neos Therapeutics, Inc. (NASDAQ:NEOS) - Wall Street Lion (NASDAQ:NEOS)
wslnews.com - November 23 at 9:35 AM
News IconMarket Focus: Checking Indicators on Shares of Neos Therapeutics Inc (NEOS) - MicroCap Wired (NASDAQ:NEOS)
www.microcapwired.com - November 22 at 6:33 PM
News IconWilliams %R Check on Shares of Neos Therapeutics Inc (NEOS) - MicroCap Wired (NASDAQ:NEOS)
www.microcapwired.com - November 22 at 10:40 AM
finance.yahoo.com logoNEOS THERAPEUTICS, INC. Financials (NASDAQ:NEOS)
finance.yahoo.com - November 19 at 6:29 PM
News IconNeos Therapeutics seeks US FDA approval for NT-0201 to treat ADHD (NASDAQ:NEOS)
www.pharmabiz.com - November 19 at 9:00 AM
streetinsider.com logoNeos Therapeutics (NEOS) Announces Submission of NT-0201 NDA to U.S. FDA (NASDAQ:NEOS)
www.streetinsider.com - November 18 at 5:58 PM
4-traders.com logoNeos Therapeutics Submits NDA for Amphetamine Extended-Release Liquid Suspension Drug Candidate, NT-0201, for the Treatment of ADHD (NASDAQ:NEOS)
www.4-traders.com - November 18 at 5:58 PM
seekingalpha.com logoNeos Therapeutics: Only One Thing Is Missing - Seeking Alpha (NASDAQ:NEOS)
seekingalpha.com - November 18 at 9:33 AM
globenewswire.com logoNeos Therapeutics Submits NDA for Amphetamine Extended ... - GlobeNewswire (press release) (NASDAQ:NEOS)
globenewswire.com - November 18 at 9:33 AM
streetinsider.com logoNeos Therapeutics (NEOS) Announces Submission of NT-0201 NDA to U.S. FDA - StreetInsider.com (NASDAQ:NEOS)
www.streetinsider.com - November 17 at 6:02 PM
News IconTrading Lines in Focus for Neos Therapeutics Inc (NEOS) - Yankee Analysts (NASDAQ:NEOS)
yankeeanalysts.com - November 17 at 10:14 AM
reuters.com logoBRIEF-Neos Therapeutics says submits NDA for Amphetamine extended-release ... - Reuters (NASDAQ:NEOS)
www.reuters.com - November 17 at 10:14 AM
News IconWhat The Charts Are Saying About Neos Therapeutics, Inc. (NASDAQ:NEOS) - Wall Street Lion (NASDAQ:NEOS)
wslnews.com - November 17 at 10:14 AM
globenewswire.com logoNeos Therapeutics Submits NDA for Amphetamine Extended-Release Liquid Suspension Drug Candidate, NT-0201 ... - GlobeNewswire (press release) (NASDAQ:NEOS)
globenewswire.com - November 17 at 10:14 AM
capitalcube.com logoETFs with exposure to Neos Therapeutics, Inc. : November 14, 2016 (NASDAQ:NEOS)
www.capitalcube.com - November 14 at 6:41 PM
biz.yahoo.com logoNEOS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:NEOS)
biz.yahoo.com - November 14 at 10:31 AM
marketexclusive.com logoNeos Therapeutics, Inc. (NASDAQ:NEOS) Files An 8-K Reports Third Quarter 2016 Financial Results (NASDAQ:NEOS)
marketexclusive.com - November 12 at 8:57 AM
einnews.com logoNeos Therapeutics Reports Third Quarter 2016 Financial Results (NASDAQ:NEOS)
www.einnews.com - November 12 at 8:57 AM
capitalcube.com logoNeos Therapeutics, Inc. :NEOS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016 (NASDAQ:NEOS)
www.capitalcube.com - November 11 at 6:08 PM
News IconNeos Therapeutics reports 3Q loss - Yahoo Sports (NASDAQ:NEOS)
sports.yahoo.com - November 11 at 8:58 AM
News IconStock Tearing Ahead Mid-day: Neos Therapeutics, Inc. (NASDAQ:NEOS) - CSZ News (NASDAQ:NEOS)
cincysportszone.com - November 10 at 6:09 PM
News IconInvesting Focus: Indicators in View on Shares of Neos Therapeutics Inc (NEOS) - MicroCap Wired (NASDAQ:NEOS)
www.microcapwired.com - November 10 at 6:09 PM
News IconNeos Therapeutics Reports Third Quarter 2016 Financial Results - EconoTimes (NASDAQ:NEOS)
www.econotimes.com - November 10 at 6:09 PM
marketexclusive.com logoNeos Therapeutics, Inc. (NASDAQ:NEOS) Files An 8-K Reports Third Quarter 2016 Financial Results - Market Exclusive (NASDAQ:NEOS)
marketexclusive.com - November 10 at 6:09 PM
nasdaq.com logoNeos Therapeutics Reports Third Quarter 2016 Financial Results - Nasdaq (NASDAQ:NEOS)
www.nasdaq.com - November 10 at 9:26 AM
sg.finance.yahoo.com logoNeos Therapeutics reports 3Q loss (NASDAQ:NEOS)
sg.finance.yahoo.com - November 10 at 9:26 AM

Social

What is Neos Therapeutics' stock symbol?

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

Where is Neos Therapeutics' stock going? Where will Neos Therapeutics' stock price be in 2017?

4 equities research analysts have issued 12-month price objectives for Neos Therapeutics' shares. Their forecasts range from $15.00 to $32.00. On average, they expect Neos Therapeutics' stock price to reach $25.33 in the next twelve months.

When will Neos Therapeutics announce their earnings?

Neos Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 15th 2017.

Who owns Neos Therapeutics stock?

Neos Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (8.19%), DSC Advisors L.P. (4.32%), Deerfield Management Co. (1.43%), State Street Corp (0.96%), Putnam Investments LLC (0.72%) and Russell Investments Group Ltd. (0.54%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Bryant Fong, Gregory J Robitaille, Juergen Martens, Presidio Partners 2007, LP, Richard I Eisenstadt and Thomas P Mcdonnell.

Who sold Neos Therapeutics stock? Who is selling Neos Therapeutics stock?

Neos Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC and DSC Advisors L.P..

Who bought Neos Therapeutics stock? Who is buying Neos Therapeutics stock?

Neos Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., State Street Corp and Franklin Resources Inc.. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Bryant Fong, Gregory J Robitaille, Juergen Martens, Richard I Eisenstadt and Thomas P Mcdonnell.

How do I buy Neos Therapeutics stock?

Shares of Neos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Neos Therapeutics stock cost?

One share of Neos Therapeutics stock can currently be purchased for approximately $5.95.

Neos Therapeutics (NASDAQ:NEOS) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Earnings History Chart

Earnings by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Dividend History Chart

Dividend Payments by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Last Updated on 2/24/2017 by MarketBeat.com Staff